
Oric Pharmaceuticals, Inc.: updates and filings
Price
$7.36
November 20, 2026Market cap $739M
What Ploutos Investor adds for Oric Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 16, 2026Results of operationsForm8-K
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 23, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 3, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Results of operationsForm8-K
- Jul 30, 2026Shares registered for employeesFormS-8
- Jul 30, 2026Officer or director changeForm8-K
- Jun 22, 2026Officer or director change, shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 4, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 4, 2026Results of operationsForm8-K
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Mar 31, 2026Other material eventsForm8-K
- Feb 23, 2026Other material eventsForm8-K
- Feb 23, 2026Shares registered for employeesFormS-8
- Feb 23, 2026Annual reportfor the period to Dec 31, 2025Form10-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 16, 2026 | 8-K | Results of operations | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 23, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 3, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | 8-K | Results of operations | Document |
| Jul 30, 2026 | S-8 | Shares registered for employees | Document |
| Jul 30, 2026 | 8-K | Officer or director change | Document |
| Jun 22, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 4, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 4, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 31, 2026 | 8-K | Other material events | Document |
| Feb 23, 2026 | 8-K | Other material events | Document |
| Feb 23, 2026 | S-8 | Shares registered for employees | Document |
| Feb 23, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 13, 2019.
The full analysis
What do Oric Pharmaceuticals's filings show?
The filings are where every one of Oric Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.